Protein Drugs - A Global Strategic Business Report - new market research report published
2012-11-23 10:30:27 - Protein Drugs - A Global Strategic Business Report - a new market research report on companiesandmarkets.com
The global market for Protein Drugs is forecast to reach US$158.2 billion by 2015. Key factors driving market growth include improved drug efficacy and safety, patent position, speed-to-market, advances in the field of biotechnology and positive outcomes of protein drugs in treating critical diseases.
Protein drugs, also referred to as biologics, are pharmaceuticals based upon proteins. Advent of proteomics and high-throughput
screening has helped expand the range of protein drugs available for disease treatment and management. And this matched against the growing base of aging population with deteriorating health conditions, has helped boost the popularity of protein drugs. Development of protein drugs transformed the treatment process for various diseases such as anemia, autoimmune diseases, cancer, multiple sclerosis, arthritis, psoriasis, cardiology, diabetes, hormone replacement, hepatitis, metabolic disorders, and reproductive medicine. In Europe and the US, over 160 types of licensed protein drugs are already commercialized and nearly 400 types of protein drugs are in the process of development. Protein drugs had attracted the attention of pharmaceutical manufacturers based on its specificity, bioreactivity, safety and tremendous success rate. Still, continuous improvements are being made with respect to the formulation and drug delivery method. One area where experts are particularly noticing interest is in non-injectable solutions such as rectal, oral, ocular, buccal, transdermal, intranasal and pulmonary routes. New protein drug delivery methods are expected to further increase patient compliance, and expand its applications into several disease therapeutic markets. While growth of protein drugs is healthy, industry participants face several new and serious challenges in foreseeable future. Notably, several blockbuster drugs will lose patent exclusivity in short-to-medium term and pipeline of pioneer, game changing drugs remain slim.
Amid a mixed bag of growth and challenges, global market for protein drugs is projected to reach US$158.2 billion by 2015. United States represents the largest market for protein drugs worldwide, as stated by the new market research report on Protein Drugs. Relative resilience of the protein drugs market to economic cycles is higher than in comparison with many other businesses, given its growing indispensability in the practice of health care worldwide. Not recession, but generic competition is expected to cause erosion in revenues for major players in this space. Most of the drug classes such as, insulin and analogues, erythropoietins, granulocyte colony-stimulating factors, interferons and human growth hormones have already lost patent protection. Patents expiration of key protein drugs, and worldwide endeavors to reduce healthcare expenditure opens the market to biosimilar versions of first generation drugs.
Segment wise, Antibodies is expected to register impressive growth to become the leading drug class in the worldwide protein therapeutics market by 2015.
Advances in information, bio and nanotechnologies are fueling the development of innovative drug delivery systems for protein therapeutics. The success of protein therapeutics rests partially on the effectiveness of protein delivery devices. Besides increasing patient compliance, advances in protein drug delivery are likely to expand several drug markets. In addition, for brand originators, innovative drug delivery devices provide an opportunity to differentiate their products in the marketplace.
Insurance reimbursement will continue to remain a key factor influencing growth in protein drugs market. Presently, worldwide hospitals and healthcare providers are fraught with reimbursement pressures and lowered direct government spending due to constricted budgets. Market acceptance of products is heavily dependent on the ability of consumers to obtain adequate reimbursement from third-party payers. Several drug companies are committed to ink partnerships in emerging markets in a bid to increase patient access to their medicines.
The report titled Protein Drugs: A Global Strategic Business Report provides a comprehensive review of current market trends, key growth drivers, challenges, recent product introductions/corporate developments and profiles of key market participants. The report provides annual sales estimates and projections for Protein Drugs for the following geographic markets - US, and Rest of World. Key drug classes analyzed include Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Others.
Major players profiled in the report include Abbott Laboratories Inc, Alexion Pharmaceuticals Inc, Amgen Inc, Biogen Idec, Bristol-Myers Squibb Company, Medarex Inc, Crucell N.V., Dendreon Corporation, Eli Lilly and Company, Emergent BioSolutions Inc, Genentech Inc, Johnson & Johnson, Centocor Ortho Biotech Inc, MedImmune Inc, Merck Serono S.A., Schering-Plough Corporation, UCB Group, Unigene Laboratories Inc, Vaccinogen Inc, among others.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.